3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
5
Stomach Neoplasms
4
HER2-positive Breast Cancer
3
Neoplasms
2
Hematologic Neoplasms
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
HER2-positive Gastric Cancer
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Stem Cell Transplantation
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Trastuzumab
2
Cyclophosphamide
2
trametinib
1
thymoglobulin
1
peginterferon alfa-2b
1
orelabrutinib
1
luspatercept
1
kalinox
1
dabrafenib
1
atezolizumab
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Tretinoin
1
Standard of Care
1
Practice Guidelines as Topic
1
Patient Comfort
1
Palliative Care
1
Melphalan
1
Immunotherapy, Adoptive
1
Immunoglobulins
1
Imipenem
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Ferric Oxide, Saccharated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Hematologic Neoplasms
×
Trastuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled